Amneal Pharmaceuticals, Inc. - News - Press Releases

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Dec 06, 2005

IMPAX Receives Final FDA Approval for Generic Version of OxyContin in 10mg, 20mg and 40mg Strengths; Sixth Approval in 2005

Nov 07, 2005

IMPAX Signs Exclusive Supply and Distribution Agreement with DAVA Pharmaceuticals for Oxycodone Hydrochloride Extended Release Tablets

Oct 24, 2005

IMPAX Announces Shire's Lawsuit Related to Generic Version of Adderall XR

Sep 29, 2005

IMPAX Prevails in Alza's Lawsuit Related to Generic Version of Ditropan XL

Sep 14, 2005

IMPAX Receives Final Approval for Generic Version of Glucophage(R) XR

Sep 02, 2005

IMPAX Announces Alza's Lawsuit Related to Generic Version Of Concerta

Aug 05, 2005

IMPAX Receives Notice of Delisting from Nasdaq

Aug 03, 2005

IMPAX Provides Further Update of Progress in Filing 10-K and 10-Q and Estimates of Results

Jun 27, 2005

IMPAX Laboratories, Inc. Agrees to Sell $75 Million of 3.5% Senior Subordinated Convertible Debentures Due 2012; Proceeds to be Used to Repay 1.250% Convertible Senior Subordinated Debentures Due 2024

Jun 20, 2005

IMPAX to Increase Existing Credit Facility

May 23, 2005

IMPAX Receives Notice of Additional Delinquency for Failure to File Form 10-Q

May 04, 2005

IMPAX Provides Updates on Progress to File 10-K and Related Matters

May 02, 2005

IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 2005

Apr 18, 2005

IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005

Apr 06, 2005

IMPAX Receives Notice of Possible Delisting for Failure to File Form 10-K

Apr 01, 2005

IMPAX Names Arthur A. Koch, Jr. Senior Vice President, Finance, and Chief Financial Officer

Mar 31, 2005

IMPAX Announces Delay in 10-K Filing

Mar 24, 2005

IMPAX to Present at the Smith Barney Citigroup 2005 Healthcare Conference

Mar 14, 2005

IMPAX to File 2004 10-K Filing Extension

Mar 09, 2005

IMPAX Announces Biovail's Lawsuit Related to Generic Versions of Wellbutrin XL

Mar 04, 2005

IMPAX to Present at the Raymond James Institutional Investor Conference

Mar 03, 2005

IMPAX Launches Generic Version of OxyContin Controlled Release 80 mg Tablets

Mar 02, 2005

IMPAX Receives Final FDA Approval for Generic Version of Dantrium; Global Division to Launch Immediately

Feb 28, 2005

IMPAX Files Motion to Intervene as Defendant in Litigation Related to Generic Allegra-D

Feb 04, 2005

IMPAX to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

Feb 02, 2005

IMPAX Receives Tentative FDA Approval for Generic Version of Ditropan XL; First Approval in 2005

Jan 05, 2005

IMPAX to Present at the JP Morgan Healthcare Conference

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.71.0.1